Your browser doesn't support javascript.
loading
Real-world outcomes of advanced melanoma patients not represented in phase III trials.
van Zeijl, Michiel C T; Ismail, Rawa K; de Wreede, Liesbeth C; van den Eertwegh, Alfonsus J M; de Boer, Anthonius; van Dartel, Maaike; Hilarius, Doranne L; Aarts, Maureen J B; van den Berkmortel, Franchette W P J; Boers-Sonderen, Marye J; de Groot, Jan-Willem B; Hospers, Geke A P; Kapiteijn, Ellen; Piersma, Djura; van Rijn, Rozemarijn S; Suijkerbuijk, Karijn P M; Ten Tije, Albert J; van der Veldt, Astrid A M; Vreugdenhil, Gerard; Haanen, John B A G; Wouters, Michel W J M.
Afiliación
  • van Zeijl MCT; Scientific department, Dutch Institute for Clinical Auditing, Leiden, The Netherlands.
  • Ismail RK; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • de Wreede LC; Scientific department, Dutch Institute for Clinical Auditing, Leiden, The Netherlands.
  • van den Eertwegh AJM; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
  • de Boer A; Medicines Evaluation Board, Utrecht, The Netherlands.
  • van Dartel M; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
  • Hilarius DL; Department of Medical Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Aarts MJB; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
  • van den Berkmortel FWPJ; Medicines Evaluation Board, Utrecht, The Netherlands.
  • Boers-Sonderen MJ; Medicines Evaluation Board, Utrecht, The Netherlands.
  • de Groot JB; Department of Pharmacy, Red Cross Hospital, Beverwijk, The Netherlands.
  • Hospers GAP; Department of Medical Oncology, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Kapiteijn E; Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands.
  • Piersma D; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van Rijn RS; Isala Oncology Center, Isala, Zwolle, The Netherlands.
  • Suijkerbuijk KPM; Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands.
  • Ten Tije AJ; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • van der Veldt AAM; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands.
  • Vreugdenhil G; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
  • Haanen JBAG; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Wouters MWJM; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands.
Int J Cancer ; 147(12): 3461-3470, 2020 12 15.
Article en En | MEDLINE | ID: mdl-32559817
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Terapia Molecular Dirigida / Antineoplásicos Inmunológicos / Melanoma Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Int J Cancer Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Terapia Molecular Dirigida / Antineoplásicos Inmunológicos / Melanoma Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Int J Cancer Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos